Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
P47898
UPID:
5HT5A_HUMAN
Alternative names:
Serotonin receptor 5A
Alternative UPACC:
P47898; Q2M2D2
Background:
The 5-hydroxytryptamine receptor 5A, also known as the Serotonin receptor 5A, plays a pivotal role in neurotransmission and hormonal regulation. This receptor, encoded by the gene with accession number P47898, is integral to the modulation of serotonin, a key neurotransmitter involved in a myriad of physiological processes. The receptor's activity is mediated through G proteins, highlighting its importance in signal transduction pathways.
Therapeutic significance:
Understanding the role of 5-hydroxytryptamine receptor 5A could open doors to potential therapeutic strategies. Its involvement in serotonin signaling makes it a compelling target for the development of drugs aimed at treating neurological and psychiatric conditions.